Clinical trial
Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease: Single-center, Open, Prospective, Single-arm, Feasibility, Investigator-initiated Trial)
NCT06474013 is registered in ClinicalTrials.gov with Korea University Anam Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease: Single-center, Open, Prospective, Single-arm, Feasibility, Investigator-initiated Trial)
- Lead sponsor
- Korea University Anam Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- September 1, 2024
- Completion date
- July 31, 2025
- Enrollment
- 15 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.